Serious adverse drug reactions at two children's hospitals in South Africa.
Adverse drug reaction
HIV
Pharmacoepidemiology
Prevalence
Trigger tool
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
04 01 2020
04 01 2020
Historique:
received:
06
08
2019
accepted:
16
12
2019
entrez:
6
1
2020
pubmed:
7
1
2020
medline:
15
5
2021
Statut:
epublish
Résumé
The high HIV prevalence in South Africa may potentially be shaping the local adverse drug reaction (ADR) burden. We aimed to describe the prevalence and characteristics of serious ADRs at admission, and during admission, to two South African children's hospitals. We reviewed the folders of children admitted over sequential 30-day periods in 2015 to the medical wards and intensive care units of each hospital. We identified potential ADRs using a trigger tool developed for this study. A multidisciplinary team assessed ADR causality, type, seriousness, and preventability through consensus discussion. We used multivariate logistic regression to explore associations with serious ADRs. Among 1050 patients (median age 11 months, 56% male, 2.8% HIV-infected) with 1106 admissions we found 40 serious ADRs (3.8 per 100 drug-exposed admissions), including 9/40 (23%) preventable serious ADRs, and 8/40 (20%) fatal or near-fatal serious ADRs. Antibacterials, corticosteroids, psycholeptics, immunosuppressants, and antivirals were the most commonly implicated drug classes. Preterm neonates and children in middle childhood (6 to 11 years) were at increased risk of serious ADRs compared to infants (under 1 year) and term neonates: adjusted odds ratio (aOR) 5.97 (95% confidence interval 1.30 to 27.3) and aOR 3.63 (1.24 to 10.6) respectively. Other risk factors for serious ADRs were HIV infection (aOR 3.87 (1.14 to 13.2) versus HIV-negative) and increasing drug count (aOR 1.08 (1.04 to 1.12) per additional drug). Serious ADR prevalence in our survey was similar to the prevalence found elsewhere. In our setting, serious ADRs were associated with HIV-infection and the antiviral drug class was one of the most commonly implicated. Similar to other sub-Saharan African studies, a large proportion of serious ADRs were fatal or near-fatal. Many serious ADRs were preventable.
Sections du résumé
BACKGROUND
The high HIV prevalence in South Africa may potentially be shaping the local adverse drug reaction (ADR) burden. We aimed to describe the prevalence and characteristics of serious ADRs at admission, and during admission, to two South African children's hospitals.
METHODS
We reviewed the folders of children admitted over sequential 30-day periods in 2015 to the medical wards and intensive care units of each hospital. We identified potential ADRs using a trigger tool developed for this study. A multidisciplinary team assessed ADR causality, type, seriousness, and preventability through consensus discussion. We used multivariate logistic regression to explore associations with serious ADRs.
RESULTS
Among 1050 patients (median age 11 months, 56% male, 2.8% HIV-infected) with 1106 admissions we found 40 serious ADRs (3.8 per 100 drug-exposed admissions), including 9/40 (23%) preventable serious ADRs, and 8/40 (20%) fatal or near-fatal serious ADRs. Antibacterials, corticosteroids, psycholeptics, immunosuppressants, and antivirals were the most commonly implicated drug classes. Preterm neonates and children in middle childhood (6 to 11 years) were at increased risk of serious ADRs compared to infants (under 1 year) and term neonates: adjusted odds ratio (aOR) 5.97 (95% confidence interval 1.30 to 27.3) and aOR 3.63 (1.24 to 10.6) respectively. Other risk factors for serious ADRs were HIV infection (aOR 3.87 (1.14 to 13.2) versus HIV-negative) and increasing drug count (aOR 1.08 (1.04 to 1.12) per additional drug).
CONCLUSIONS
Serious ADR prevalence in our survey was similar to the prevalence found elsewhere. In our setting, serious ADRs were associated with HIV-infection and the antiviral drug class was one of the most commonly implicated. Similar to other sub-Saharan African studies, a large proportion of serious ADRs were fatal or near-fatal. Many serious ADRs were preventable.
Identifiants
pubmed: 31901244
doi: 10.1186/s12887-019-1892-x
pii: 10.1186/s12887-019-1892-x
pmc: PMC6942333
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
3Subventions
Organisme : PEPFAR
Pays : United States
Références
Medicine (Baltimore). 2016 May;95(19):e3437
pubmed: 27175644
Br J Clin Pharmacol. 2015 Oct;80(4):818-26
pubmed: 25475751
Pediatrics. 2012 Jun;129 Suppl 3:S153-60
pubmed: 22661762
S Afr Med J. 2016 Dec 01;106(12):1222-1229
pubmed: 27917768
BMC Pediatr. 2015 Jul 15;15:83
pubmed: 26173560
Drug Saf. 2004;27(11):819-29
pubmed: 15350153
Br J Clin Pharmacol. 2015 Oct;80(4):808-17
pubmed: 25677107
BMC Pediatr. 2016 Jul 07;16:81
pubmed: 27387547
Hosp Pharm. 1992 Jun;27(6):538
pubmed: 10118597
Sao Paulo Med J. 2011 May;129(3):153-64
pubmed: 21755250
Curr Opin Allergy Clin Immunol. 2001 Aug;1(4):311-6
pubmed: 11964706
BMC Med. 2013 Nov 07;11:237
pubmed: 24228998
Pediatrics. 1988 Jul;82(1):24-9
pubmed: 3380598
PLoS One. 2012;7(12):e50127
pubmed: 23226510
S Afr Med J. 2017 Feb 27;107(3):219-226
pubmed: 28281427
Drug Saf. 2005;28(10):851-70
pubmed: 16180936
Br J Clin Pharmacol. 2001 Jul;52(1):77-83
pubmed: 11453893
PLoS One. 2012;7(3):e24061
pubmed: 22403604
J Trop Pediatr. 2019 Aug 1;65(4):389-396
pubmed: 30544245
J Clin Pharmacol. 2018 Oct;58 Suppl 10:S36-S47
pubmed: 30248196